Aura Biosciences, Inc. (NASDAQ:AURA) CFO Sells $302,325.93 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) CFO Julie B. Feder sold 25,131 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $12.03, for a total value of $302,325.93. Following the completion of the transaction, the chief financial officer now directly owns 134,276 shares in the company, valued at $1,615,340.28. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Aura Biosciences Stock Performance

NASDAQ:AURA opened at $11.40 on Thursday. The firm’s 50-day moving average is $8.87 and its 200-day moving average is $8.15. Aura Biosciences, Inc. has a 52-week low of $5.99 and a 52-week high of $12.38. The company has a market cap of $564.79 million, a price-to-earnings ratio of -6.13 and a beta of 0.37.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.04. Equities analysts predict that Aura Biosciences, Inc. will post -1.7 EPS for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of AURA. Levin Capital Strategies L.P. increased its holdings in Aura Biosciences by 194.5% in the 2nd quarter. Levin Capital Strategies L.P. now owns 327,466 shares of the company’s stock valued at $2,476,000 after buying an additional 216,266 shares during the period. Dimensional Fund Advisors LP raised its position in Aura Biosciences by 20.0% in the second quarter. Dimensional Fund Advisors LP now owns 250,375 shares of the company’s stock worth $1,892,000 after purchasing an additional 41,711 shares in the last quarter. American International Group Inc. lifted its stake in Aura Biosciences by 27.4% during the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares during the period. Long Focus Capital Management LLC boosted its holdings in Aura Biosciences by 113.4% during the second quarter. Long Focus Capital Management LLC now owns 1,057,188 shares of the company’s stock valued at $7,992,000 after purchasing an additional 561,766 shares in the last quarter. Finally, Virtu Financial LLC acquired a new stake in Aura Biosciences during the first quarter valued at approximately $144,000. 96.75% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

AURA has been the topic of a number of recent analyst reports. HC Wainwright lifted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Friday, October 18th. BTIG Research lifted their target price on shares of Aura Biosciences from $21.00 to $24.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Cowen restated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. Finally, Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a report on Monday, September 16th. Five analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $23.00.

About Aura Biosciences

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.